DiscoverCell & Gene: The PodcastThe Future of Adenovector-Based Therapies with Precigen's Helen Sabzevari, Ph.D.
The Future of Adenovector-Based Therapies with Precigen's Helen Sabzevari, Ph.D.

The Future of Adenovector-Based Therapies with Precigen's Helen Sabzevari, Ph.D.

Update: 2025-01-30
Share

Description

We love to hear from our listeners. Send us a message.

Helen Sabzevari, Ph.D., President and CEO of Precigen, joins Host, Erin Harris to discuss how the company utilizes gorilla adenovirus vectors. These vectors offer significant advantages in delivering large genetic payloads, a crucial factor in developing effective gene therapies. Sabzevari also discusses Precigen's recent BLA submission for PRGN-2012, which includes Phase 1/2 pivotal study results where over 50% of patients achieved Complete Response and more than 85% experienced decreased surgical interventions.

Subscribe to the podcast!
Apple | Spotify | YouTube

Visit my website: Cell & Gene

Connect with me on LinkedIn

Comments 
In Channel
loading
00:00
00:00
x

0.5x

0.8x

1.0x

1.25x

1.5x

2.0x

3.0x

Sleep Timer

Off

End of Episode

5 Minutes

10 Minutes

15 Minutes

30 Minutes

45 Minutes

60 Minutes

120 Minutes

The Future of Adenovector-Based Therapies with Precigen's Helen Sabzevari, Ph.D.

The Future of Adenovector-Based Therapies with Precigen's Helen Sabzevari, Ph.D.

Erin Harris